Intercept Pharmaceuticals (NASDAQ: ICPT )
has had a wild ride to redefine all wild rides. While this biotech was
definitely interesting and undervalued on the merits of its bile acid
therapeutic OCA for primary biliary cirrhosis (PBC), the unexpected
success of a Phase IIb study in nonalcoholic steatohepatitis (NASH) has
sent the shares into a new orbit. While the company's recent
presentation at the JPMorgan Healthcare Conference spooked investors
with talk of possibly pursuing a partner for the NASH program, this may
ultimately be the best way to maximize value for the application.
Click here to read the full article at The Motley Fool:
Intercept's Thoughts Of Partnering NASH Make Sense
No comments:
Post a Comment